Clinical benefits versus shortcomings of diltiazem once-daily in the chronotherapy of cardiovascular diseases

Author： Ezeugo Ugochukwu   Glasser Stephen P  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.3, 2009-02, pp. : 485-491

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics of Once-Daily Molsidomine: From Immediate-Release to Prolonged-Release Once-Daily Formulations

By Herchuelz A.  

American Journal of Drug Delivery, Vol. 2, Iss. 2, 2004-01 ,pp. : 131-141

Adis International

Access to resources Recommend Favorite

Once-daily tobramycin the TOPIC of the day

By  

Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Efficacy and Safety Assessment of a Novel Once-Daily Tablet Formulation of Tramadol: A Randomised, Controlled Study versus Twice-Daily Tramadol in Patients with Osteoarthritis of the Knee

By Gérald Mongin  

Clinical Drug Investigation, Vol. 24, Iss. 9, 2004-01 ,pp. : 545-558

Adis International

Access to resources Recommend Favorite

A Patient Preference Study Comparing Two Extended-Release Morphine Sulfate Formulations (Once-Daily Kadian versus Twice-Daily MS Contin) for Cancer Pain

By Kerr R.O.  

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 25-32

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective

By Delea Thomas E.  

PharmacoEconomics, Vol. 25, Iss. 4, 2007-01 ,pp. : 329-342

Adis International

Access to resources Recommend Favorite